Literature DB >> 20233870

Colitis-associated cancer is dependent on the interplay between the hemostatic and inflammatory systems and supported by integrin alpha(M)beta(2) engagement of fibrinogen.

Kris A Steinbrecher1, Netanel A Horowitz, Elizabeth A Blevins, Kelley A Barney, Maureen A Shaw, Eleana Harmel-Laws, Fred D Finkelman, Matthew J Flick, Malinda D Pinkerton, Kathryn E Talmage, Keith W Kombrinck, David P Witte, Joseph S Palumbo.   

Abstract

A link between colitis and colon cancer is well established, but the mechanisms regulating inflammation in this context are not fully defined. Given substantial evidence that hemostatic system components are powerful modulators of both inflammation and tumor progression, we used gene-targeted mice to directly test the hypothesis that the coagulation factor fibrinogen contributes to colitis-associated colon cancer in mice. This fundamental provisional matrix protein was found to be an important determinant of colon cancer. Fibrinogen deficiency resulted in a dramatic diminution in the number of colonic adenomas formed following azoxymethane/dextran sodium sulfate challenge. More detailed analyses in mice expressing a mutant form of fibrinogen that retains clotting function, but lacks the leukocyte integrin receptor alpha(M)beta(2) binding motif (Fibgamma(390-396A)), revealed that alpha(M)beta(2)-mediated engagement of fibrin(ogen) is mechanistically coupled to local inflammatory processes (e.g., interleukin-6 elaboration) and epithelial alterations that contribute to adenoma formation. Consistent with these findings, the majority of Fibgamma(390-396A) mice developed no discernable adenomas, whereas penetrance was 100% in controls. Furthermore, the adenomas harvested from Fibgamma(390-396A) mice were significantly smaller than those from control mice and less proliferative based on quantitative analyses of mitotic indices, suggesting an additional role for fibrin(ogen) in the growth of established adenomas. These studies show, for the first time, a unique link between fibrin(ogen) and the development of inflammation-driven malignancy. Given the importance of antecedent inflammation in the progression of numerous cancers, these studies suggest that therapies targeting fibrin(ogen)-alpha(M)beta(2) interactions may be useful in preventing and/or treating this important subset of malignancies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20233870      PMCID: PMC4288842          DOI: 10.1158/0008-5472.CAN-09-3465

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  44 in total

1.  Wound-healing defects in mice lacking fibrinogen.

Authors:  A F Drew; H Liu; J M Davidson; C C Daugherty; J L Degen
Journal:  Blood       Date:  2001-06-15       Impact factor: 22.113

2.  Disrupted barrier function through epithelial cell apoptosis.

Authors:  Joerg-Dieter Schulzke; Christian Bojarski; Sebastian Zeissig; Frank Heller; Alfred H Gitter; Michael Fromm
Journal:  Ann N Y Acad Sci       Date:  2006-08       Impact factor: 5.691

Review 3.  Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition.

Authors:  J A Nagy; L F Brown; D R Senger; N Lanir; L Van de Water; A M Dvorak; H F Dvorak
Journal:  Biochim Biophys Acta       Date:  1989-02

4.  Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production.

Authors:  B Siegmund; G Fantuzzi; F Rieder; F Gamboni-Robertson; H A Lehr; G Hartmann; C A Dinarello; S Endres; A Eigler
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2001-10       Impact factor: 3.619

5.  Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4.

Authors:  S T Smiley; J A King; W W Hancock
Journal:  J Immunol       Date:  2001-09-01       Impact factor: 5.422

Review 6.  Inflammation and coagulation in inflammatory bowel disease: The clot thickens.

Authors:  Silvio Danese; Alfredo Papa; Simone Saibeni; Alessandro Repici; Alberto Malesci; Maurizio Vecchi
Journal:  Am J Gastroenterol       Date:  2006-11-13       Impact factor: 10.864

Review 7.  Cancer in inflammatory bowel disease.

Authors:  Jianlin Xie; Steven H Itzkowitz
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

8.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer.

Authors:  Sergei Grivennikov; Eliad Karin; Janos Terzic; Daniel Mucida; Guann-Yi Yu; Sivakumar Vallabhapurapu; Jürgen Scheller; Stefan Rose-John; Hilde Cheroutre; Lars Eckmann; Michael Karin
Journal:  Cancer Cell       Date:  2009-02-03       Impact factor: 31.743

9.  Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis.

Authors:  Boryana K Popivanova; Kazuya Kitamura; Yu Wu; Toshikazu Kondo; Takashi Kagaya; Shiuchi Kaneko; Masanobu Oshima; Chifumi Fujii; Naofumi Mukaida
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

10.  Loss of epithelial RelA results in deregulated intestinal proliferative/apoptotic homeostasis and susceptibility to inflammation.

Authors:  Kris A Steinbrecher; Eleana Harmel-Laws; Raquel Sitcheran; Albert S Baldwin
Journal:  J Immunol       Date:  2008-02-15       Impact factor: 5.422

View more
  75 in total

Review 1.  Protease-activated receptor 2 signaling in inflammation.

Authors:  Andrea S Rothmeier; Wolfram Ruf
Journal:  Semin Immunopathol       Date:  2011-10-06       Impact factor: 9.623

Review 2.  Fibrinogen Is at the Interface of Host Defense and Pathogen Virulence in Staphylococcus aureus Infection.

Authors:  Ya-Ping Ko; Matthew J Flick
Journal:  Semin Thromb Hemost       Date:  2016-04-07       Impact factor: 4.180

3.  Thrombin promotes diet-induced obesity through fibrin-driven inflammation.

Authors:  Anna K Kopec; Sara R Abrahams; Sherry Thornton; Joseph S Palumbo; Eric S Mullins; Senad Divanovic; Hartmut Weiler; A Phillip Owens; Nigel Mackman; Ashley Goss; Joanne van Ryn; James P Luyendyk; Matthew J Flick
Journal:  J Clin Invest       Date:  2017-07-24       Impact factor: 14.808

4.  Factor XIII activity mediates red blood cell retention in venous thrombi.

Authors:  Maria M Aleman; James R Byrnes; Jian-Guo Wang; Reginald Tran; Wilbur A Lam; Jorge Di Paola; Nigel Mackman; Jay L Degen; Matthew J Flick; Alisa S Wolberg
Journal:  J Clin Invest       Date:  2014-07-01       Impact factor: 14.808

5.  Fibrin deposition following bile duct injury limits fibrosis through an αMβ2-dependent mechanism.

Authors:  Nikita Joshi; Anna K Kopec; Jessica L Ray; Holly Cline-Fedewa; Atta Nawabi; Timothy Schmitt; Rance Nault; Timothy R Zacharewski; Cheryl E Rockwell; Matthew J Flick; James P Luyendyk
Journal:  Blood       Date:  2016-02-26       Impact factor: 22.113

6.  Amelioration of Duchenne muscular dystrophy in mdx mice by elimination of matrix-associated fibrin-driven inflammation coupled to the αMβ2 leukocyte integrin receptor.

Authors:  Berta Vidal; Esther Ardite; Mònica Suelves; Vanessa Ruiz-Bonilla; Anna Janué; Matthew J Flick; Jay L Degen; Antonio L Serrano; Pura Muñoz-Cánoves
Journal:  Hum Mol Genet       Date:  2012-03-01       Impact factor: 6.150

7.  Combination of Preoperative Plasma Fibrinogen and Neutrophil-to-Lymphocyte Ratio (the F-NLR Score) as a Prognostic Marker of Locally Advanced Rectal Cancer Following Preoperative Chemoradiotherapy.

Authors:  Yanwu Sun; Yiyi Zhang; Zhekun Huang; Huiming Lin; Xingrong Lu; Ying Huang; Pan Chi
Journal:  World J Surg       Date:  2020-06       Impact factor: 3.352

8.  Gene signature distinguishes patients with chronic ulcerative colitis harboring remote neoplastic lesions.

Authors:  Joel Pekow; Urszula Dougherty; Yong Huang; Edward Gometz; Jeff Nathanson; Greg Cohen; Shawn Levy; Masha Kocherginsky; Nanda Venu; Maria Westerhoff; John Hart; Amy E Noffsinger; Stephen B Hanauer; Roger D Hurst; Alessandro Fichera; Loren J Joseph; Qiang Liu; Marc Bissonnette
Journal:  Inflamm Bowel Dis       Date:  2013-03       Impact factor: 5.325

9.  Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations.

Authors:  Nathalie Magnus; Delphine Garnier; Brian Meehan; Serge McGraw; Tae Hoon Lee; Maxime Caron; Guillaume Bourque; Chloe Milsom; Nada Jabado; Jacquetta Trasler; Rafal Pawlinski; Nigel Mackman; Janusz Rak
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-11       Impact factor: 11.205

10.  Pretreatment plasma fibrinogen as an independent prognostic indicator of prostate cancer patients treated with androgen deprivation therapy.

Authors:  Y Wang; W Yin; Z Wang; J Huang; J Pan; Y Zhu; F Xu; X Shao; J Sha; Y Cai; Q Liu; B Dong; W Xue; Y Huang
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-03-08       Impact factor: 5.554

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.